M&A / Deals BioAegis and Prenosis partner for inflammatory disease therapies Pharmaceutical TechnologyBioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases.M&A / DealsImmunology & InflammationRead full story pharminent April 22, 2026 (Last updated: April 22, 2026) Pharmaceutical Technology BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases. M&A / DealsImmunology & InflammationRead full story Post navigation Previous: Medicare obesity drug pilot extended after insurer pushbackNext: BioAegis and Prenosis partner for inflammatory disease therapies Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
